The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 10/12.5 mg

Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/12.5 mg

Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/25 mg

NDC	**Lot Number**	**Expiration Date**	**Strength**	**Configuration/ Count**
0071-3112-23	FG5379	08/2024	10/12.5 mg	1 x 90 count bottle
0071-0222-23	EA6686	04/2022	10/12 .5 mg	1 x 90 count bottle
0071-5212-23	FG5381	08/2024	20/12.5 mg	1 x 90 count bottle
0071-0220-23	EA6665	04/2022	20/12.5 mg	1 x 90 count bottle
0071-0220-23	CN0640	04/2022	20/12 .5 mg	1 x 90 count bottle
0071-0223-23	ET6974	02/2023	20/25 mg	1 x 90 count bottle

quinapril and hydrochlorothiazide tablets, 20/25 mg

quinapril HCl/hydrochlorothiazide tablets, 20/12.5 mg

quinapril HCl/hydrochlorothiazide tablets, 20/25 mg

NDC	**Lot Number**	**Expiration Date**	**Strength**	**Configuration/ Count**
59762-5225-9	FE3714	02/2023	20/ 25 mg	1 x 90 count bottle
59762-0220-1	DN6931	03/2023	20/12.5 mg	1 x 90 count bottle
59762-0220-1	ED3904	03/2023	20/12.5 mg	1 x 90 count bottle
59762-0220-1	ED3905	03/2023	20/12.5 mg	1 x 90 count bottle
59762-0223-1	DP3414	02/2023	20/25 mg	1 x 90 count bottle

Pfizer Inc. is recalling the above referenced lots of **Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, quinapril and hydrochlorothiazide tablets,** and **quinapril HCl/hydrochlorothiazidetablets.**

Pfizer initiated this recall due to the presence of n-nitroso-quinapril above the Acceptable Daily Intake (ADI) level. Pfizer conducted a toxicological evaluation to establish an ADI, which incorporated numerous conservative assumptions. Pfizer also conducted a Product Assessment, including an evaluation of safety surveillance data. Based on Pfizer's assessments, the benefit/risk of quinapril and hydrochlorothiazide remains positive based on currently available data. Although a potential excess lifetime cancer risk from n-nitroso-quinapril may exist, it is considered to be low based on currently available data.

The recall of the above referenced lots of **Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, quinapril and hydrochlorothiazide tablets,** and **quinapril HCl/hydrochlorothiazide tablets** is being conducted to the **Consumer/User level.**